InvestorsHub Logo
Followers 467
Posts 26918
Boards Moderated 2
Alias Born 09/11/2006

Re: surf1944 post# 20

Monday, 09/05/2011 10:44:24 PM

Monday, September 05, 2011 10:44:24 PM

Post# of 62
Theravance, Inc. (Nasdaq:THRX)
Total Insider buying: $2,019,604.88
SEC Filing
Latest Chart
GlaxoSmithKline Plc which is a 10% owner of the company purchased more shares at an average price of $19.71 in early August and shares saw a low of $16.59 before bouncing to $18.55, then finally settling at $17.50.

There are three upcoming milestones for the company highlighted in the calendar, including two separate approval decisions for Telavancin that are under review at the European Medicines Agency.

Theravance is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule medicines in therapeutic areas of respiratory disease, bacterial infections and central nervous system.

http://seekingalpha.com/article/288897-10-big-healthcare-stocks-being-snapped-up-by-insiders?source=yahoo


surf's up......crikey



Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent THRX News